SUMMARY One hundred and thirty coded sera, 60 from patients with systemic lupus erythematosus (SLE) and 70 from patients with other autoimmune rheumatic diseases were tested for deoxyribonucleic acid (DNA) binding activity by five different types of assay. These were enzyme linked immunosorbent assay (ELISA) (distinguishing IgG and IgM anti-ssDNA and anti-dsDNA), Crithidia luciliae, a nitrocellulose filter assay, the Amersham kit, and another modified Farr assay, the radioimmunoassay (RIA) (UK). The Crithidia test was the most specific, none of the controls was positive, but the least sensitive (13% positive only). The RIA (UK) was the most sensitive (57% positive). (Sigma, Poole, Dorset) (50 ig/ml in distilled water) and incubated for one hour at 37°C. Each well was then washed three times with phosphate buffered saline (PBS) (Flow, Ayrshire, Scotland) before the addition of 50 RI of dsDNA (10 Fig/ml) or ssDNA (5 [ig/ml), both in PBS. The dsDNA was prepared by treating calf thymus DNA (Sigma) with 1 U/4g S1 nuclease (Sigma) for 30 minutes at 37°C. The ssDNA was prepared by boiling calf thymus DNA for 10 minutes and cooling on ice for 15 minutes. After overnight incubation at 4°C the plates were washed three times with PBS. These were then treated with 100 RI of 
It is now 10 years since an international workshop reported the measurement of anti-DNA antibodies on a set of eight sera by 12 It also became obvious in this study' that preparation of the antigen is important in influencing the results in some assays. Stollar has reviewed this subject in some detail.2 Most obviously, contamination of dsDNA with single stranded (ss) DNA will seriously interfere with the assay.
In the past 10 years some assays, such as the Crithidia luciliae test, new in 1976, have become very popular. In addition, an important technique, the enzyme linked immunosorbent assay (ELISA) has become increasingly available.
We therefore felt it was time to reappraise the status of anti-DNA assays, especially of those likely to be available to practising rheumatologists within populations of patients they are likely to see. We have approached the problems in a simple, functional way by asking which, among a variety of assays now available, are of value in distinguishing systemic lupus erythematosus (SLE) from non-lupus disease and which of these assays reflect disease activity in SLE itself?
Patients, materials, and methods
PATI ENTS
One hundred and thirty coded sera were prepared having been stored at -20°C. Sixty sera from patients with SLE were studied. Each patient fulfilled four or more of the American Rheumatism Association's revised criteria for the classification of disease.3 Fifty seven of these patients were female, three male, and their ages ranged between 18 and 66 years. The clinical activity of the patients was assessed by a method published elsewhere4 which distinguishes between inactive (11 patients in the group studied), mildly active (29 patients), moderately active (16 patients), and severely active (four patients) disease. The details of this index are shown in Table 1 . Its derivation has been discussed previously.5 The patients were also subdivided (XX28 096 00) and applying a vacuum to filter the contents of each well through the 0-45 im membrane bonded to its base. Each well was washed through with a total volume of 1-0 ml of 10 mM TRIS buffer saline pH 7-6 to remove any unbound radiolabelled DNA. The millititre plates were dried at 37°C for one hour and the filters punched out. The nitrocellulose filters were cleared in liquid scintillant fluid Otiphase MB (LKB, UK) and counted in a beta counter. Using the appropriate controls the total amount of DNA bound was calculated and expressed as Rg DNA bound/ml of neat sera. The upper limit of normal for this assay was set at 4-5 ,ug DNA bound/ml serum. This represents a figure greater than 3SD above the mean for 30 
Results
The results of the four ELISA, three RIA, and the Crithidia luciliae immunofluorescence test have been analysed in several ways. In Table 2 the number of sera with raised DNA antibody levels in the SLE and disease control groups is shown. All of the assays showed strong statistically significant differences between the SLE and the combined non-SLE patients (p<0-01). Although the Crithidia luciliae test was the most selective, no 'false' positives being found in any of the control groups, it was also the least sensitive as only 13% of the patients with SLE were positive. In contrast, the RIA (UK) identified 57% of the patients with SLE but also gave a slightly higher number of 'false' positives amongst the disease controls (10%). Of the other tests, the clearest separation between SLE and combined non-lupus groups was found with the anti-dsDNA IgG ELISA (33% v 4%) and the Amersham kit (38% v 3%). Analysis of the subgroups is hampered by the relatively small numbers of patients (n= 10) with primary Sjogren's syndrome, myositis, scleroderma, and autoimmune liver disease. In the group with rheumatoid arthritis (n=30) all the DNA binding assays distinguished between SLE and RA (p<0 (5) . The assays with the fewest 'false' positives were the Crithidia luciliae and Amersham kit. In contrast, the disease control most likely to have raised DNA binding was the autoimmune liver disease group.
As might be expected those patients whose sera gave positive results in one assay were not necessarily positive in all the other tests. We therefore determined how many patients had raised IgM or IgG dsDNA antibodies, or both, by ELISA (62%) 3 (4) 7 (1())
3 (4) 2 (3) o (() (n =71)) fp<)-05: *-p<0-O2: *`p<O-0l: *'*p<)-(O)I. by y2 comparing ea.ch control group with thc SLE group. NS=not significaint. Tables 4 and 5 . In Table 4 the SLE and disease control groups were best distinguished by the IgG anti-ssDNA and anti- Table 5 demonstrates the differences between the means for each assay with respect to the clinical activity index. It is evident that the severely ill patients form distinct groups and that good guides to clinical activity are the IgG antidsDNA ELISA, RIA (UK), RIA (NCF), the Amersham kit, and the Crithidia luciliae test.
A comparison of the absolute values obtained in each assay is shown in Table 6 . The best correlations obtained (r values greater than 0-5) were between IgG anti-ssDNA and anti-dsDNA (both by ELISA) and anti-ssDNA and the RIA (UK). In contrast, the ELISA IgM anti-ssDNA and anti-dsDNA were the assays with the fewest number of significant correlations.
Analysis of the lupus patients by subdividing them into those with and without the major clinical features listed in the 'Patients' section, showed few statistically significant correlations with the various assay methods. Anti-dsDNA antibodies measured by ELISA correlated with photosensitive skin rash (p=O-OO9), and, similarly, the RIA (UK), Amersham kit, and Crithidia luciliae assays were significantly associated with renal disease (p=0O01, p=0-002, and p=0003 respectively).
Discussion
The simultaneous description by several laboratories almost thirty years ago of anti-DNA antibodies in the serum of lupus patients'1-7 has generated a wide ranging debate about their relevance to the pathogenesis of SLE and the utility of their detection. In this study we 12 participating centres tested sera from eight patients using up to six different assays, including Farr and Millipore filter binding assays, RIA using a second antibody, and immunofluorescence assays. As was noted, 'on no serum was there total agreement between all the assays performed'. The serum from the patient with the most active lupus (patient No 6), who also had the highest DNA binding recorded in the original referral centre, gave very high levels in most of the assays used. It was surprising that many assays recorded high values in the pooled normal serum and the serum from patients with inactive lupus.
Although an ELISA which could be used to determine antibodies to dsDNA had been described by the time of the workshop,18 this technique was not included in the study. An ELISA, however, does offer several potential advantages. It avoids problems of radioactive contamination and disposal, should not be affected by non-immunoglobulin serum components which can bind DNA, is easily measurable, and can be used to distinguish between the different isotypes of DNA antibodies. It has been suggested more recently that the ELISA technique is more sensitive than the immunofluorescent Crithidia luciliae assay, haemagglutination, and fluid phase radioimmunoassays. ' In their study of 154 lupus sera these authors found that 94% of patients with active SLE and 70% of sera from patients with inactive disease were positive, as were 2-5% of normal persons. This matches a similar analysis of 141 patients using an ELISA method,'9 which found that 85% (active and inactive) were positive for anti-DNA antibodies, as were 3-3% of 268 normal sera tested. In contrast, our own results showed a much lower number of positive sera by both ELISA (25-37%) and RIA (28-57%).
Furthermore, the similarity in the results between the RIA (NCF) and IgG anti-dsDNA ELISA, for example, suggests that there is little difference in the utility of detection by these very different techniques. The variation in the ELISA results of our study and those of previous reports may reflect methodological differences or variation in the lupus populations studied, or both.
The question of patient selection must be considered. In the past most authors have stressed the links between raised anti-dsDNA antibody levels and renal disease in SLE. 34 
